1,4-dimethyl-5-nitronaphthalene | 24055-41-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,4-dimethyl-5-nitronaphthalene
• 英文别名: 5-nitro-1,4-dimethylnaphthalene；1,4-Dimethyl-5-nitronaphthalin；Naphthalene, 1,4-dimethyl-5-nitro-
• CAS: 24055-41-2
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: SAJWXTKNTLLLRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,4-二甲基萘 在 硝酸 、 乙酸酐 作用下， 以100%的产率得到1,4-dimethyl-5-nitronaphthalene
  参考文献：
  名称：

  Eberson, Lennart; Radner, Finn, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1986, vol. 40, # 1, p. 71 - 78

  摘要：

  DOI：

文献信息

• NO₂⁺ Nitration Mechanism of Aromatic Compounds:  Electrophilic vs Charge-Transfer Process
  作者：Mutsuo Tanaka、Eiko Muro、Hisanori Ando、Qiang Xu、Masahiro Fujiwara、Yoshie Souma、Yoichi Yamaguchi

  DOI：10.1021/jo991538u

  日期：2000.5.1

  to shed light on the controversial aromatic nitration mechanism, electrophilic vs charge-transfer process. The NO(2)(+) nitration of 1,8-dimethylnaphthalene showed a drastic regioselectivity change depending on the reaction temperature, where ortho-regioselectivity at -78 degrees C and para-regioselectivity at 0 degrees C were considered to reflect the electrophilic and the direct or alternative charge-transfer

  为了揭示有争议的芳香族硝化机理，亲电与电荷转移过程，对NO（2）BF（4）和NOBF（4）的甲基萘的硝化进行了研究。1,8-二甲基萘的NO（2）（+）硝化显示出剧烈的区域选择性变化，具体取决于反应温度，其中-78度的邻位选择性和0度的对位选择性被认为反映了亲电性和分别采用直接或替代的电荷转移方法，因为通过与电荷转移过程中的NO（2）（+）硝化反应相同的反应中间体进行的NO（+）硝化导致对位区域选择性，而与反应温度无关。氧化还原电位甲基萘的NO（2）（+）硝化高于1，在较低的温度下，8-二甲基萘与1,8-二甲基萘具有相似的邻位选择性增强，因此反映了亲电过程。另一方面，氧化还原电势低于1,8-二甲基萘的甲基萘的NO（2）（+）硝化显示对位区域选择性类似于NO（+）硝化，表明直接或替代的电荷转移过程。在强酸的存在下，直接电荷转移过程将被质子化抑制，在1,8-二甲基萘的NO（2）（+）硝化中观察到
• 17BetaHSD Type 5 Inhibitor
  申请人：Niimi Tatsuya

  公开号：US20110071146A1

  公开（公告）日：2011-03-24

  To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

  提供一种新颖和优秀的方法，用于基于对17βHSD类型5的选择性抑制活性，治疗和/或预防前列腺癌、良性前列腺增生、痤疮、脂溢性皮炎、多毛症、秃发、脱发、早熟、肾上腺增生、多囊卵巢综合症、乳腺癌、肺癌、子宫内膜异位症、平滑肌瘤等疾病。发现一种N-磺酰基吲哚衍生物，其中吲哚环在其碳原子上被羧基取代，或者被羧基取代的低烷基或低烯基取代，具有强大的选择性抑制17βHSD类型5的活性，可能成为治疗和/或预防良性前列腺增生、前列腺癌等疾病的治疗剂和/或预防剂，而不伴随着由于睾酮降低而产生的不良药物反应，因此本发明得以完成。
• 17BetaHSD TYPE 5 INHIBITOR
  申请人：Niimi Tatsuya

  公开号：US20090181960A1

  公开（公告）日：2009-07-16

  To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone, and the present invention has thus been completed.

  提供一种新颖优良的方法，用于基于对17βHSD type 5的选择性抑制活性，治疗和/或预防前列腺癌、良性前列腺增生、痤疮、皮脂溢出、多毛症、脱发、早熟、肾上腺增生、多囊卵巢综合症、乳腺癌、肺癌、子宫内膜异位症、平滑肌瘤等疾病。发现一种N-磺酰基吲哚衍生物，其中吲哚环在其碳原子上被羧基、羧基取代的低碳基或羧基取代的低烯基取代，具有强大的选择性抑制17βHSD type 5的活性，可以成为治疗剂和/或预防剂，用于治疗良性前列腺增生、前列腺癌等疾病，不会伴随着由于睾酮减少而引起的不良药物反应，因此本发明已经完成。
• 17 BETA HSD TYPE 5 INHIBITOR
  申请人：Astellas Pharma Inc.

  公开号：EP1990335A1

  公开（公告）日：2008-11-12

  To provide a novel and excellent method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, leiomyoma and the like based on selective inhibitory activity against 17βHSD type 5. It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent for benign prostatic hyperplasia, prostatic cancer and the like without accompanying adverse drug reactions due to a decrease in testosterone; and the present invention has thus been completed.

  提供一种基于对 17βHSD 5 型的选择性抑制活性的治疗和/或预防前列腺癌、良性前列腺增生、痤疮、脂溢性皮炎、多毛症、秃头、脱发、性早熟、肾上腺肥大、多囊卵巢综合征、乳腺癌、肺癌、子宫内膜异位症、子宫肌瘤等疾病的新型优良方法。 研究发现，一种 N-磺酰基吲哚衍生物，其吲哚环的碳原子上被羧基、羧基取代的低级烷基或羧基取代的低级烯基取代，对 17βHSD 5 型具有强效的选择性抑制活性，可成为良性前列腺增生、前列腺癌等的治疗剂和/或预防剂，且不会因睾酮减少而伴随药物不良反应；本发明由此完成。
• US7855225B2
  申请人：——

  公开号：US7855225B2

  公开（公告）日：2010-12-21